Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Keytruda

Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc (NASDAQ:SMMT) and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

This Blue-Chip Dividend Stock Is Stuck in the Tariff Crosshairs. Can Cost Cuts Save the Day?

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 billion cost-cutting plan and a $10 billion push into new therapies —moves that analysts say could revive the shares if executed well.

Do Wall Street Analysts Like Merck & Company Stock?

Do Wall Street Analysts Like Merck & Company Stock?

As Merck outperforms the broader market this year, Wall Street analysts remain optimistic about the stock's prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Analyst Believes Seagen Is Evaluating Strategic Alternatives

Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price. Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company. The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent…

Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

Merck & Co Inc (NYSE: MRK) has

1

Organisations

Summit Therapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play